Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: In vitro and in vivo results

British Journal of Cancer

Volumn 79, Issue 3-4, 1999, Pages 535-537

  Raderer, M ^b   Hamilton, G ^a   Kurtaran, A ^c   Valencak, J ^c   Haberl, I ^c   Hoffmann, O ^c   Kornek, G V ^c   Vorbeck, F ^c   Hejna, M H L ^c   Virgolini, I ^c   Scheithauer, W ^c  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c NONE

Author keywords

Lanreotide; Pancreatic cancer; Somatostatin receptors

Indexed keywords

ANGIOPEPTIN; LONG ACTING DRUG; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; DIARRHEA; ERYTHEMA; FEMALE; HUMAN; HUMAN CELL; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; METEORISM; NAUSEA; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SCINTIGRAPHY; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PEPTIDES, CYCLIC; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; SURVIVAL ANALYSIS;

EID: 0032950730     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690084     Document Type: Article

References (26)

1. American Cancer Society (1991) Cancer Facts and Figures 1991. American Cancer Society: Atlanta
2. Anthony L, Johnson D, Hande K, Shaff M, Winn S, Krozely M and Oates J (1993) Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 32: 217-223
3. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TH and Pless J (1982) SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31: 1133-1140
4. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, Kalthoff H, Lluis F, Vaysse N and Susini C (1996) Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 56: 1823-1827
5. Canobbio L, Boccardo F, Cannata D, Gallotti P and Epis R (1992) Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Cancer 69: 648-650
6. Caron P, Cogne M, Gusthiot-Joudet B, Wakim S, Catus F and Bayard F (1995) Intramuscular injections of slow release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur J Endocrinol 132: 320-325
7. Cascinu S, Del Ferro E and Catalano G (1995) A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer 71: 97-101
8. Ebert M, Friess H, Berger HG and Büchler MW (1994) Role of octreotide in the treatment of pancreatic cancer. Digestion 55 (suppl. 1): 48-51
9. Glimelius B, Hoffman K, Sjöden PO, Jacobsson G, Sellström H, Enander LK, Linne T and Svensson C (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7: 593-600
10. Hughier M, Samama G, Testart J, Mauban S, Fingerhut A, Nassar J, Houry S, Saeck D, De Mestier I and Favre JP (1992) Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). Am J Surg 164: 348-353
11. Janson ET, Gobl A, Kalkner KM and Oberg K (1996) A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res 56: 2561-2565
12. Kiljn JGM, Hoff AM, Planting AST, Verweij J, Kok T, Lamberts SWJ, Portengen H and Foekens JA (1990) Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue sandostatin: a phase II study including endocrine effects. Br J Cancer 62: 627-630
13. 123I-Tyr-3-octreotide: the Rotterdam experience wilh more than 1000 patients. Eur J Nucl Med 20: 716-731
14. Kuhn JM, Legrand A, Ruiz JM, Obach R, De-Ronzan J and Thomas F (1994) Pharmacokinetic and pharmacodynamic properties of a long acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmacol 38: 213-219
15. Marek J, Hana V, Krsek M, Justova V, Catus F and Thomas F (1994) Long-term treatment of acromegaly with the slow release somatostatin analogue lanreotide. Eur J Endocrinol 131: 20-26
16. National Cancer Institute (1991) Annual Cancer Statistics Review 1973-1988. NIH publication no. 91-2789. Department of Health and Human Services: Bethesda, MD
17. Qin Y, Schally AV and Willems G (1992) Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC-160. Int J Cancer 52: 791-796
18. Reubi JC, Horisberger U, Essed JE, Jeekel J, Klijn JGH and Lamberts SWJ (1988) Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology 95: 760-763
19. Reubi JC, Krenning E, Lamberts SWJ and Kvols L (1990) Somatostatin receptors in malignant tissues. Steroid Biochem Mol Biol 37: 1073-1077
20. Reubi JC, Horisberger U and Laissue J (1994) High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumour-host interaction? Int J Cancer 56: 681-688
21. Scatchard G (1949) The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51: 660-672
22. Taylor JE, Theveniau MA, Bashirzadeh R, Reisine T and Eden PA (1994) Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides 15: 1229-1236
23. Viollet C, Prevost G, Maubert E, Faivre-Bauman A, Gardette R, Kordon C, Loudes C, Slama A and Epelbaum J (1995) Molecular pharmacology of somatostatin receptors. Fundam Clin Pharmacol 9: 107-113
24. Virgolini I, Yang Q, Li S, Angelberger P, Neumold N, Niederle B, Scheithauer W and Valent P (1994) Cross-competition between vasoactive intestinal peptide (VIP) and somatostatin for binding to tumor cell receptors. Cancer Res 54: 690-700
25. Warshaw AL and Fernandez-del Castillo C (1992) Pancreatic carcinoma. N Engl J Med 326: 455-465
26. Weckbecker G, Liu R, Tolesvai L and Bruns C (1992) Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res 52: 4973-4978